title: Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine.
abstract: The approval or clinical evaluation of several new agents - cabazitaxel, abiraterone acetate, enzalutamide, sipuleucel-T, and radium-223 - has significantly changed the management of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to or after docetaxel-based chemotherapy. All of these agents have resulted in a significant survival benefit as compared to their control group. However, treatment responses might differ depending on the associated comorbidities and the extent and biological aggressiveness of the disease. Furthermore, treatment-associated side effects differ between the various drugs. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. It is the aim of the current article to i) summarize the data of established treatment options in mCRPC, ii) highlight new developments in medical treatment, iii) provide clinically useful algorithms for the daily routine, and iv) point out future developments in medical treatment.
authors.affiliation: Department of Urology, University Hospital Cologne, Cologne, Germany.
authors.forename: Jan
authors.initials: J
authors.lastname: Herden
authors.forename: Isabell
authors.initials: I
authors.lastname: Heidegger
authors.forename: Pia
authors.initials: P
authors.lastname: Paffenholz
authors.forename: Daniel
authors.initials: D
authors.lastname: Porres
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma / Q000517:prevention & control* / Q000556:secondary*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D017410:Practice Guidelines as Topic; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents